King's College London

Research portal

Efflux pumps in Mycobacterium tuberculosis and their inhibition to tackle antimicrobial resistance

Research output: Contribution to journalReview articlepeer-review

Original languageEnglish
Pages (from-to)57-68
Number of pages12
JournalTrends in Microbiology
Volume30
Issue number1
DOIs
Accepted/In press2021
PublishedJan 2022

Bibliographical note

Funding Information: The authors would like to extend their thanks to the Biotechnology and Biological Sciences Research Council for funding this work (grant number BB/T007648/1 ) as part of Mark Laws’ postdoctoral research associate (PDRA) position within the Rahman laboratory. Publisher Copyright: © 2021 Elsevier Ltd Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

King's Authors

Abstract

Tuberculosis (TB), an infectious disease caused by the bacterium Mycobacterium tuberculosis, was the leading cause of mortality worldwide in 2019 due to a single infectious agent. The growing threat of strains of M. tuberculosis untreatable by modern antibiotic regimens only exacerbates this problem. In response to this continued public health emergency, research into methods of potentiating currently approved antimicrobial agents against resistant strains of M. tuberculosis is an urgent priority, and a key strategy in this regard is the design of mycobacterial efflux pump inhibitors (EPIs). This review summarises the current state of knowledge surrounding drug-related efflux pumps in M. tuberculosis and presents recent updates within the field of mycobacterial EPIs with a view to aiding the design of an effective adjunct therapy to overcome efflux-mediated resistance in TB.

View graph of relations

© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454